Lupus Science and Medicine Podcast
Health & Wellness Podcasts
Lupus Science and Medicine is a global, peer reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus.
Location:
United Kingdom
Genres:
Health & Wellness Podcasts
Description:
Lupus Science and Medicine is a global, peer reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus.
Twitter:
@Lupus_SM
Language:
English
Website:
http://lupus.bmj.com/
Email:
podcast.admin@bmj.com
To RNase or Not to RNase: That Is the Question
Duration:00:14:05
A decision-aid facilitates patient understanding of benefits vs. risk of hydroxychloriquine use as part of routine care for lupus
Duration:00:15:05
Dual dsDNA testing may be needed to fully understand patient disease status
Duration:00:21:40
Is Anifrolumab an effective treatment for lupus nephritis?
Duration:00:12:44
Which one is better at controlling lupus: Belimumab or Anifrolumab?
Duration:00:12:38
Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis
Duration:00:23:27
Testing a new measure of lupus improvement that encompasses the patients’ perspectives and doctors’ evaluations
Duration:00:18:05
Understanding Lupus: Exploring the Differences between Type 1 and Type 2 Symptoms
Duration:00:20:25
Unpacking Lupus Treatment: How Quickly Does Anifrolumab Start Working? Insights from TULIP Trials
Duration:00:14:42
Biomarker reduction indicates treatment response to Belimumab
Duration:00:14:35
Biomarker reduction indicates treatment response to Belimumab
Duration:00:14:36
Mesenchymal stromal cells: a potential new SLE treatment option?
Duration:00:17:57
Using patient registries to estimate SLE incidence rate in the USA
Duration:00:16:52
Defining remission in systemic lupus erythematosus
Duration:00:19:21
What’s the relationship between self-efficacy and quality of life in SLE patients?
Duration:00:20:19
Challenging but achievable: reaching Low Lupus Disease Activity State (LLDAS) in childhood-onset SLE
Duration:00:20:09
Could a high fiber diet positively impact the gut microbiome of SLE patients?
Duration:00:15:37
A new biomarker for cognitive dysfunction in SLE?
Duration:00:16:00
Screening for cognitive dysfunction in SLE patients
Duration:00:16:17
Highlights of ACR Convergence 2021
Duration:00:18:59